By Evercyte GmbH
To get in touch with Evercyte GmbH, simply fill out the form below.
Subscribe to Supplier
Senolytic Drug Testing using cell-based assays
Evercyte’s drug screening services include senolytic and senomorphic drug testing using cell-based assays for efficacy and toxicity.
This service offers a fast-track development route from initial senolytic candidate hit to lead cell-based assays, testing senolytic activity using human cells from different organs and tissues as well as different inducers of cellular senescence.
Senolytics, agents that selectively induce apoptosis of senescent cells that accumulate in tissues with ageing and at sites of pathology in chronic ailments, are now considered game changers across a range of age-associated diseases, including frailty, cardiac dysfunction, vascular hyper reactivity and calcification, diabetes mellitus, liver steatosis, osteoporosis, vertebral disk degeneration, and pulmonary fibrosis.
Senolytics and senomorphics/senostatics (suppression of senescence markers or preventing secondary senescence) have become increasingly important in life sciences, including pharmaceutical industry and biotech companies, clinical and academic research groups, with senolytic agents being tested in several proof-of-concept clinical trials.
Evercyte’s senolytics-based drug screening services meet emerging needs for new tools to identify novel agents and elucidate their modes of action, including drug screening with relevant and standardizable in vitro models.
Senolytic service features
Evercyte’s senolytic efficacy and toxicity assays are based on human cells from different organs and tissues that are readily available. These include skin fibroblasts, lung fibroblasts, umbilical vein endothelial cells, podocytes, microvascular endothelial cells, keratinocytes, kidney epithelial cells, and mesenchymal stem cells (MSCs).
A comprehensive portfolio of pre-established and validated tests for characterization of senescent phenotypes includes:
- Cellular morphology
- Expression of SA-ß-galactosidase
- Marker gene transcription including p16, p21, etc.
- Analysis of cell cycle progression/BrdU incorporation
- Analysis of senescence associated secretory phenotypes (SASPs) through expression or secretion of MCP1, Il6, IL8, and of miRNAs, etc.
Further, Evercyte offers several options for induction of senescence including in vitro propagation until cells enter replicative senescence (growth until replicative senescence) or induction of stress-induced premature senescence (SIPS) using doxorubicin.
The new service leverages from Evercyte’s more than 25 years of work and experience with cellular senescence that have seen their scientists publish more than 130 peer reviewed articles in the field of senolytics.
Evercyte maintains constant availability of all tools, reagents and materials (including cells) that are required for identification and characterization of senolytic drugs.
Combined with pre-established techniques and assays that can be performed without delay, this means Evercyte can offer very fast turnaround times with direct comparison of different drugs.
Excellent data quality assured as customer derived samples are handled by highly qualified cell biologists and teams with many years’ accumulated experience with normal/telomerized cells, senescence, and characterization of senescent phenotypes.